EPS for Concert Pharmaceuticals, Inc. (CNCE) Expected At $-0.61; Shorts at IMMUPHARMA PLC ORDINARY SHARES UNITED K (IMMPF) Raised By 14.8%

April 18, 2018 - By Dolores Ford

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Logo

IMMUPHARMA PLC ORDINARY SHARES UNITED K (OTCMKTS:IMMPF) had an increase of 14.8% in short interest. IMMPF’s SI was 28,700 shares in April as released by FINRA. Its up 14.8% from 25,000 shares previously. With 8,700 avg volume, 3 days are for IMMUPHARMA PLC ORDINARY SHARES UNITED K (OTCMKTS:IMMPF)’s short sellers to cover IMMPF’s short positions. The SI to IMMUPHARMA PLC ORDINARY SHARES UNITED K’s float is 0.03%. The stock decreased 74.41% or $1.57 during the last trading session, reaching $0.54. It is down 0.00% since April 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report $-0.61 EPS on May, 1.They anticipate $0.01 EPS change or 1.67% from last quarter’s $-0.6 EPS. After having $-0.26 EPS previously, Concert Pharmaceuticals, Inc.’s analysts see 134.62% EPS growth. The stock increased 1.66% or $0.33 during the last trading session, reaching $20.16. About 192,768 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since April 18, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Investors sentiment increased to 2.62 in 2017 Q4. Its up 1.44, from 1.18 in 2017Q3. It improved, as 10 investors sold Concert Pharmaceuticals, Inc. shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Aqr Cap Mngmt Ltd reported 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Schwab Charles Invest Mngmt invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Moreover, Laurion Cap Mgmt L P has 0.09% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 711,540 shares. Ingalls & Snyder Ltd Co invested in 1.57% or 1.31 million shares. Moreover, Gotham Asset Ltd has 0.01% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 15,530 shares. California State Teachers Retirement has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 28,249 shares. Bogle Invest Limited Partnership De stated it has 292,010 shares. First Quadrant Limited Partnership Ca owns 0.02% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 37,814 shares. Acadian Asset Ltd reported 0.03% stake. Plante Moran Fincl Advisors Ltd Com owns 0.03% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 2,000 shares. 793 are held by Comml Bank Of Montreal Can. Eam Ltd Liability Company reported 0.25% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Connecticut-based Cubist Systematic Strategies Ltd Liability Com has invested 0.03% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Balyasny Asset Management Ltd Co has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Bvf Il reported 1.97M shares.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 24 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, September 22 by TH Capital. Aegis Capital maintained it with “Buy” rating and $2500 target in Thursday, June 29 report. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by Aegis Capital on Wednesday, September 9. The rating was downgraded by UBS to “Neutral” on Monday, November 9. The firm has “Buy” rating given on Friday, October 20 by H.C. Wainwright. Stifel Nicolaus maintained Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) on Thursday, October 19 with “Buy” rating. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Monday, September 18. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. UBS maintained the stock with “Buy” rating in Tuesday, December 19 report. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has “Buy” rating given on Wednesday, August 12 by Brean Capital.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $468.38 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 4.96 P/E ratio. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

Since October 19, 2017, it had 0 buys, and 5 sales for $2.39 million activity. BVF PARTNERS L P/IL also bought $5.26 million worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares. $597,833 worth of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was sold by ALDRICH RICHARD on Tuesday, January 16.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>